[A18-34] Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 17.09.2018
Project no.:
A18-34
Commission:
Commission awarded on 24.05.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
HIV-1 infection in adults who are virologically-suppressed on a stable regimen for ≥ 6 months with no history of virological failure and no known or suspected resistance to any NNRTIs or INIs
Without indication for a treatment switch: indication of lesser benefit; with indication for a treatment switch: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-11 | Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-12-06 A G-BA decision was published.